Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Other Non Operating Income (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Other Non Operating Income over the past 9 years, most recently at $2.1 million for Q4 2023.

  • For Q4 2023, Other Non Operating Income rose 1008.79% year-over-year to $2.1 million; the TTM value through Dec 2023 reached $2.2 million, up 1730.33%, while the annual FY2024 figure was $4.1 million, 51.08% up from the prior year.
  • Other Non Operating Income for Q4 2023 was $2.1 million at Corbus Pharmaceuticals Holdings, up from $183000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $12.3 million in Q4 2021 and troughed at -$4.2 million in Q4 2019.
  • A 5-year average of $768178.7 and a median of $16672.0 in 2021 define the central range for Other Non Operating Income.
  • Biggest five-year swings in Other Non Operating Income: crashed 10630.37% in 2019 and later skyrocketed 30874.77% in 2021.
  • Year by year, Other Non Operating Income stood at -$4.2 million in 2019, then surged by 99.05% to -$40000.0 in 2020, then skyrocketed by 30874.77% to $12.3 million in 2021, then tumbled by 98.49% to $186330.0 in 2022, then skyrocketed by 1008.79% to $2.1 million in 2023.
  • Business Quant data shows Other Non Operating Income for CRBP at $2.1 million in Q4 2023, $183000.0 in Q2 2023, and $728.0 in Q1 2023.